Kinase insert domain receptor: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
m (→‎top: bold)
Line 1: Line 1:
 
{{Infobox_gene}}
 
'''Kinase insert domain receptor''' ('''KDR''', a type III receptor tyrosine kinase) also known as '''vascular endothelial growth factor receptor 2''' ('''VEGFR-2''') is a [[VEGF receptor]]. ''KDR'' is the human [[gene]] encoding it. KDR has also been designated as '''CD309''' ([[cluster of differentiation]] 309). KDR is also known as Flk1 (Fetal Liver Kinase 1).
 
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = yes
| update_citations = yes
}}
 
<!-- The GNF_Protein_box is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
{{GNF_Protein_box
| image = 
| image_source = 
 
| Name = Kinase insert domain receptor (a type III receptor tyrosine kinase)
| HGNCid = 6307
| Symbol = KDR
| AltSymbols =; CD309; FLK1; VEGFR; VEGFR2
| OMIM = 191306
| ECnumber = 
| Homologene = 55639
| MGIid = 96683
| GeneAtlas_image1 = PBB_GE_KDR_203934_at_tn.png
| Function = {{GNF_GO|id=GO:0000166 |text = nucleotide binding}} {{GNF_GO|id=GO:0004872 |text = receptor activity}} {{GNF_GO|id=GO:0005021 |text = vascular endothelial growth factor receptor activity}} {{GNF_GO|id=GO:0005515 |text = protein binding}} {{GNF_GO|id=GO:0005524 |text = ATP binding}} {{GNF_GO|id=GO:0016740 |text = transferase activity}}
| Component = {{GNF_GO|id=GO:0005887 |text = integral to plasma membrane}} {{GNF_GO|id=GO:0016020 |text = membrane}}
| Process = {{GNF_GO|id=GO:0001525 |text = angiogenesis}} {{GNF_GO|id=GO:0001570 |text = vasculogenesis}} {{GNF_GO|id=GO:0006468 |text = protein amino acid phosphorylation}} {{GNF_GO|id=GO:0007169 |text = transmembrane receptor protein tyrosine kinase signaling pathway}} {{GNF_GO|id=GO:0007275 |text = multicellular organismal development}} {{GNF_GO|id=GO:0016477 |text = cell migration}} {{GNF_GO|id=GO:0030097 |text = hemopoiesis}} {{GNF_GO|id=GO:0045165 |text = cell fate commitment}} {{GNF_GO|id=GO:0045446 |text = endothelial cell differentiation}}
| Orthologs = {{GNF_Ortholog_box
    | Hs_EntrezGene = 3791
    | Hs_Ensembl = ENSG00000128052
    | Hs_RefseqProtein = NP_002244
    | Hs_RefseqmRNA = NM_002253
    | Hs_GenLoc_db = 
    | Hs_GenLoc_chr = 4
    | Hs_GenLoc_start = 55639401
    | Hs_GenLoc_end = 55686519
    | Hs_Uniprot = P35968
    | Mm_EntrezGene = 16542
    | Mm_Ensembl = ENSMUSG00000062960
    | Mm_RefseqmRNA = XM_984991
    | Mm_RefseqProtein = XP_990085
    | Mm_GenLoc_db = 
    | Mm_GenLoc_chr = 5
    | Mm_GenLoc_start = 76214954
    | Mm_GenLoc_end = 76260125
    | Mm_Uniprot = Q3UQZ6
  }}
}}
'''Kinase insert domain receptor (a type III receptor tyrosine kinase)''', also known as '''KDR''', is a human [[gene]].


<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
Line 56: Line 7:
| summary_text =  
| summary_text =  
}}
}}
==Interactions==
Kinase insert domain receptor has been shown to [[Protein-protein interaction|interact]] with [[SHC2]],<ref name=pmid10749680>{{cite journal |doi=10.1042/0264-6021:3470501 |last=Warner |first=A J |authorlink= |author2=Lopez-Dee J |author3=Knight E L |author4=Feramisco J R |author5=Prigent S A  |date=April 2000  |title=The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells |journal=Biochem. J. |volume=347 |issue=Pt 2 |pages=501–9 |publisher= |location = England| issn = 0264-6021| pmid = 10749680 | bibcode = | oclc =| id = | url = | language = | format = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=1220983 }}</ref> [[Annexin A5]]<ref name=pmid10329451>{{cite journal |last=Wen |first=Y |authorlink= |author2=Edelman J L |author3=Kang T |author4=Sachs G  |date=May 1999 |title=Lipocortin V may function as a signaling protein for vascular endothelial growth factor receptor-2/Flk-1 |journal=Biochem. Biophys. Res. Commun. |volume=258 |issue=3 |pages=713–21 |publisher= |location = UNITED STATES| issn = 0006-291X| pmid = 10329451 |doi = 10.1006/bbrc.1999.0678 | bibcode = | oclc =| id = | url = | language = | format = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> and [[SHC1]].<ref name=pmid11950700>{{cite journal |doi=10.1161/01.ATV.0000012268.84961.AD |last=Zanetti |first=Adriana |authorlink= |author2=Lampugnani Maria Grazia |author3=Balconi Giovanna |author4=Breviario Ferruccio |author5=Corada Monica |author6=Lanfrancone Luisa |author7=Dejana Elisabetta  |date=April 2002  |title=Vascular endothelial growth factor induces SHC association with vascular endothelial cadherin: a potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling |journal=Arterioscler. Thromb. Vasc. Biol. |volume=22 |issue=4 |pages=617–22 |publisher= |location = United States| issn = | pmid = 11950700 | bibcode = | oclc =| id = | url = | language = | format = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref><ref name=pmid10319320>{{cite journal |doi=10.1210/mend.13.5.0280 |last=D'Angelo |first=G |authorlink= |author2=Martini J F |author3=Iiri T |author4=Fantl W J |author5=Martial J |author6=Weiner R I  |date=May 1999 |title=16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells |journal=Mol. Endocrinol. |volume=13 |issue=5 |pages=692–704 |publisher= |location = UNITED STATES| issn = 0888-8809| pmid = 10319320 | bibcode = | oclc =| id = | url = | language = | format = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref>


==See also==
==See also==
* [[Cluster of differentiation]]
* [[VEGF receptors]]
* [[VEGF receptors]]


Line 64: Line 19:
{{PBB_Further_reading  
{{PBB_Further_reading  
| citations =  
| citations =  
*{{cite journal  | author=Petrova TV, Makinen T, Alitalo K |title=Signaling via vascular endothelial growth factor receptors. |journal=Exp. Cell Res. |volume=253 |issue= 1 |pages= 117-30 |year= 1999 |pmid= 10579917 |doi= 10.1006/excr.1999.4707 }}
*{{cite journal  |vauthors=Holmes K, Roberts OL, Thomas AM, Cross MJ | title = Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. | journal = Cell Signal. | volume = 19 | issue = 10 | pages = 2003–2012 |date=October 2007 | pmid = 17658244  | doi = 10.1016/j.cellsig.2007.05.013}}
*{{cite journal  | author=Sato Y, Kanno S, Oda N, ''et al.'' |title=Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. |journal=Ann. N. Y. Acad. Sci. |volume=902 |issue=  |pages= 201-5; discussion 205-7 |year= 2000 |pmid= 10865839 |doi=  }}
*{{cite journal  |vauthors=Petrova TV, Makinen T, Alitalo K |title=Signaling via vascular endothelial growth factor receptors. |journal=Exp. Cell Res. |volume=253 |issue= 1 |pages= 117–30 |year= 1999 |pmid= 10579917 |doi= 10.1006/excr.1999.4707 }}
*{{cite journal  | author=Zachary I, Gliki G |title=Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. |journal=Cardiovasc. Res. |volume=49 |issue= 3 |pages= 568-81 |year= 2001 |pmid= 11166270 |doi=  }}
*{{cite journal  |vauthors=Wang J, Fu X, Jiang C, Yu L, Wang M, Han W, Liu L, Wang J |title=Bone marrow mononuclear cell transplantation promotes therapeutic angiogenesis via upregulation of the VEGF-VEGFR2 signaling pathway in a rat model of vascular dementia. |journal=Behav. Brain Res. |volume=265 |pages= 171–180 |year= 2014 |pmid= 24589546 |pmc= 4000455 |doi= 10.1016/j.bbr.2014.02.033 }}
*{{cite journal  | author=Vené R, Benelli R, Noonan DM, Albini A |title=HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis. |journal=Clin. Exp. Metastasis |volume=18 |issue= 7 |pages= 533-8 |year= 2001 |pmid= 11688957 |doi=  }}
*{{cite journal  |vauthors=Sato Y, Kanno S, Oda N, etal |title=Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. |journal=Ann. N. Y. Acad. Sci. |volume=902 |issue=  1|pages= 201–5; discussion 205–7 |year= 2000 |pmid= 10865839 |doi=10.1111/j.1749-6632.2000.tb06314.x }}
*{{cite journal  | author=Lenton K |title=VEGFR-2 (KDR/Flk-1). |journal=J. Biol. Regul. Homeost. Agents |volume=16 |issue= 3 |pages= 227-32 |year= 2003 |pmid= 12456025 |doi=  }}
*{{cite journal  |vauthors=Zachary I, Gliki G |title=Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. |journal=Cardiovasc. Res. |volume=49 |issue= 3 |pages= 568–81 |year= 2001 |pmid= 11166270 |doi=10.1016/S0008-6363(00)00268-6 }}
*{{cite journal  | author=Matsumoto T, Mugishima H |title=Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. |journal=J. Atheroscler. Thromb. |volume=13 |issue= 3 |pages= 130-5 |year= 2006 |pmid= 16835467 |doi=  }}
*{{cite journal  |vauthors=Vené R, Benelli R, Noonan DM, Albini A |title=HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis. |journal=Clin. Exp. Metastasis |volume=18 |issue= 7 |pages= 533–8 |year= 2001 |pmid= 11688957 |doi=10.1023/A:1011991906685 }}
*{{cite journal  | author=Lenton K |title=VEGFR-2 (KDR/Flk-1). |journal=J. Biol. Regul. Homeost. Agents |volume=16 |issue= 3 |pages= 227–32 |year= 2003 |pmid= 12456025 |doi=  }}
*{{cite journal  |vauthors=Matsumoto T, Mugishima H |title=Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. |journal=J. Atheroscler. Thromb. |volume=13 |issue= 3 |pages= 130–5 |year= 2006 |pmid= 16835467 |doi=  10.5551/jat.13.130}}
}}
}}
{{refend}}
{{refend}}


==References==
{{Reflist}}
==External links==
* {{MeshName|Kinase+insert+domain+receptor}}
{{NLM content}}
{{PDB Gallery|geneid=3791}}
{{Clusters of differentiation}}
{{Growth factor receptors}}
{{Tyrosine kinases}}
{{Enzymes}}
{{Growth factor receptor modulators}}
{{Portal bar|Molecular and Cellular Biology|border=no}}
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = yes
| update_citations = yes
}}
{{DEFAULTSORT:Kinase Insert Domain Receptor}}
[[Category:Clusters of differentiation]]
[[Category:Tyrosine kinase receptors]]
[[Category:Tyrosine kinase receptors]]
{{WikiDoc Help Menu}}
 
{{WikiDoc Sources}}
 
{{transmembranereceptor-stub}}

Revision as of 04:24, 13 August 2017

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Kinase insert domain receptor (KDR, a type III receptor tyrosine kinase) also known as vascular endothelial growth factor receptor 2 (VEGFR-2) is a VEGF receptor. KDR is the human gene encoding it. KDR has also been designated as CD309 (cluster of differentiation 309). KDR is also known as Flk1 (Fetal Liver Kinase 1).


Interactions

Kinase insert domain receptor has been shown to interact with SHC2,[1] Annexin A5[2] and SHC1.[3][4]

See also

Further reading

  • Holmes K, Roberts OL, Thomas AM, Cross MJ (October 2007). "Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition". Cell Signal. 19 (10): 2003–2012. doi:10.1016/j.cellsig.2007.05.013. PMID 17658244.
  • Petrova TV, Makinen T, Alitalo K (1999). "Signaling via vascular endothelial growth factor receptors". Exp. Cell Res. 253 (1): 117–30. doi:10.1006/excr.1999.4707. PMID 10579917.
  • Wang J, Fu X, Jiang C, Yu L, Wang M, Han W, Liu L, Wang J (2014). "Bone marrow mononuclear cell transplantation promotes therapeutic angiogenesis via upregulation of the VEGF-VEGFR2 signaling pathway in a rat model of vascular dementia". Behav. Brain Res. 265: 171–180. doi:10.1016/j.bbr.2014.02.033. PMC 4000455. PMID 24589546.
  • Sato Y, Kanno S, Oda N, et al. (2000). "Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction". Ann. N. Y. Acad. Sci. 902 (1): 201–5, discussion 205–7. doi:10.1111/j.1749-6632.2000.tb06314.x. PMID 10865839.
  • Zachary I, Gliki G (2001). "Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family". Cardiovasc. Res. 49 (3): 568–81. doi:10.1016/S0008-6363(00)00268-6. PMID 11166270.
  • Vené R, Benelli R, Noonan DM, Albini A (2001). "HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis". Clin. Exp. Metastasis. 18 (7): 533–8. doi:10.1023/A:1011991906685. PMID 11688957.
  • Lenton K (2003). "VEGFR-2 (KDR/Flk-1)". J. Biol. Regul. Homeost. Agents. 16 (3): 227–32. PMID 12456025.
  • Matsumoto T, Mugishima H (2006). "Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis". J. Atheroscler. Thromb. 13 (3): 130–5. doi:10.5551/jat.13.130. PMID 16835467.

References

  1. ↑ Warner, A J; Lopez-Dee J; Knight E L; Feramisco J R; Prigent S A (April 2000). "The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells". Biochem. J. England. 347 (Pt 2): 501–9. doi:10.1042/0264-6021:3470501. ISSN 0264-6021. PMC 1220983. PMID 10749680.
  2. ↑ Wen, Y; Edelman J L; Kang T; Sachs G (May 1999). "Lipocortin V may function as a signaling protein for vascular endothelial growth factor receptor-2/Flk-1". Biochem. Biophys. Res. Commun. UNITED STATES. 258 (3): 713–21. doi:10.1006/bbrc.1999.0678. ISSN 0006-291X. PMID 10329451.
  3. ↑ Zanetti, Adriana; Lampugnani Maria Grazia; Balconi Giovanna; Breviario Ferruccio; Corada Monica; Lanfrancone Luisa; Dejana Elisabetta (April 2002). "Vascular endothelial growth factor induces SHC association with vascular endothelial cadherin: a potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling". Arterioscler. Thromb. Vasc. Biol. United States. 22 (4): 617–22. doi:10.1161/01.ATV.0000012268.84961.AD. PMID 11950700.
  4. ↑ D'Angelo, G; Martini J F; Iiri T; Fantl W J; Martial J; Weiner R I (May 1999). "16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells". Mol. Endocrinol. UNITED STATES. 13 (5): 692–704. doi:10.1210/mend.13.5.0280. ISSN 0888-8809. PMID 10319320.

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


Retrieved from "https://www.wikidoc.org/index.php?title=Kinase_insert_domain_receptor&oldid=1413687"